PDCD1 and obesity due to melanocortin 4 receptor deficiency: Interestingly, mice and clinical experiments have revealed a positive correlation between obesity and anti-PD-1/PD-L1 therapy in cancer patients, leading to greater survival after therapy, despite higher rates of immune dysfunction and tumor progression [170] (Table 3).